Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8526)
All Articles published online
|
Publishing Process of This Article
|
Aug 14, 2014 (publication date) through Nov 30, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i30/10338.htm |
| Number | Citing Articles |
| 1 |
Liya Zhou, Jianzhong Zhang, Zhiqiang Song, Lihua He, Yanqing Li, Jiaming Qian, Peng Bai, Yan Xue, Ye Wang, Sanren Lin. Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial. Helicobacter 2016; 21(2): 91 doi: 10.1111/hel.12242
|
| 2 |
Adrian G. McNicholl, Javier Molina‐Infante, Alfredo J. Lucendo, José Luis Calleja, Ángeles Pérez‐Aisa, Inés Modolell, Xavier Aldeguer, Margalida Calafat, Luis Comino, Mercedes Ramas, Ángel Callejo, Carlos Badiola, Jordi Serra, Javier P. Gisbert. Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: A randomized, double‐blind, placebo‐controlled trial. Helicobacter 2018; 23(5) doi: 10.1111/hel.12529
|
| 3 |
P Malfertheiner, F Megraud, C A O'Morain, J P Gisbert, E J Kuipers, A T Axon, F Bazzoli, A Gasbarrini, J Atherton, D Y Graham, R Hunt, P Moayyedi, T Rokkas, M Rugge, M Selgrad, S Suerbaum, K Sugano, E M El-Omar. Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report. Gut 2017; 66(1): 6 doi: 10.1136/gutjnl-2016-312288
|
| 4 |
Ricardo S. Vieira-Pires, Patricia M. Morgan, Ankit Choraria, Chinnappan Gandhimathi, Antonysamy Michael, Tiago Ôchoa-Pires, Jafar Salimian, Sentila Rajan, Meenatchisundaram Subramani. IgY-Technology: Production and Application of Egg Yolk Antibodies. 2021; : 237 doi: 10.1007/978-3-030-72688-1_16
|
| 5 |
Saman Alhooei, Hafez Tirgar Fakheri, Vahid Hosseini, Iradj Maleki, Tarang Taghvaei, Seyed Mohammad Valizadeh, Zohreh Bari. A Comparison between Hybrid and Concomitant Regimens for Helicobacter Pylori Eradication: A Randomized Clinical Trial. Middle East Journal of Digestive Diseases 2016; 8(3): 219 doi: 10.15171/mejdd.2016.24
|
| 6 |
Joon Sung Kim, Sung Min Park, Byung‐Wook Kim. Sequential or concomitant therapy for eradication of Helicobacter pylori infection: A systematic review and meta‐analysis. Journal of Gastroenterology and Hepatology 2015; 30(9): 1338 doi: 10.1111/jgh.12984
|
| 7 |
Zhiqiang Song, Liya Zhou, Jianzhong Zhang, Lihua He, Peng Bai, Yan Xue. Hybrid Therapy as First‐Line Regimen for Helicobacter pylori Eradication in Populations with High Antibiotic Resistance Rates. Helicobacter 2016; 21(5): 382 doi: 10.1111/hel.12294
|
| 8 |
Su Young Kim, Duck Joo Choi, Jun-Won Chung. Antibiotic treatment for <italic>Helicobacter pylori</italic>: Is the end coming?. World Journal of Gastrointestinal Pharmacology and Therapeutics 2015; 6(4): 183-198 doi: 10.4292/wjgpt.v6.i4.183
|
| 9 |
Diego Reyes, Javier Ortiz, Eduardo Fuentes-López, Sigall Budnik, Vicente Gándara, Andrea Gallardo, María Francisca Seydewitz, Roberto Candia, José Ignacio Vargas, María Paz Rollan, Javiera Godoy, Antonio Rollan, Rodrigo Mansilla, Alex Arenas, Javier Chahuán, Alberto Espino, Margarita Pizarro, Arnoldo Riquelme. Terapias cuádruples son superiores a terapia triple estándar en primera línea de erradicación de Helicobacter pylori en Chile. Gastroenterología y Hepatología 2022; 45(7): 515 doi: 10.1016/j.gastrohep.2021.11.010
|
| 10 |
|
| 11 |
Jung Wan Choe, Sung Woo Jung, Seung Young Kim, Jong Jin Hyun, Young Kul Jung, Ja Seol Koo, Hyung Joon Yim, Sang Woo Lee. Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton‐pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea. Helicobacter 2018; 23(2) doi: 10.1111/hel.12466
|
| 12 |
Stella I. Smith, Christian Schulz, Rose Ugiagbe, Roland Ndip, Yakhya Dieye, Marcis Leja, Charles Onyekwere, Dennis Ndububa, Abraham Ajayi, Tolulope Funbi Jolaiya, Hyasinta Jaka, Mashiko Setshedi, Revathi Gunturu, Jesse Abiodun Otegbayo, Naima Lahbabi-Amrani, Anthony Oluwole Arigbabu, Violet Kayamba, Pueya Abdulrashid Nashidengo. <i>Helicobacter pylori</i> Diagnosis and Treatment in Africa: The First Lagos Consensus Statement of the African Helicobacter and Microbiota Study Group. Digestive Diseases 2024; 42(3): 240 doi: 10.1159/000537878
|
| 13 |
David Itskoviz, Doron Boltin, Haim Leibovitzh, Tsachi Tsadok Perets, Doron Comaneshter, Arnon Cohen, Yaron Niv, Zohar Levi. Smoking increases the likelihood of Helicobacter pylori treatment failure. Digestive and Liver Disease 2017; 49(7): 764 doi: 10.1016/j.dld.2017.03.010
|
| 14 |
Teresa Fasciana, Cinzia Calà, Celestino Bonura, Enza Di Carlo, Domenica Matranga, Giuseppe Scarpulla, Michele Manganaro, Salvatore Camilleri, Anna Giammanco. Resistance to clarithromycin and genotypes in Helicobacter pylori strains isolated in Sicily.
Journal of Medical Microbiology
2015; 64(11): 1408 doi: 10.1099/jmm.0.000163
|
| 15 |
María R. Baroni, Pamela Bucci, Rita N. Giani, Antonela Giusti, Fabian A. Tedeschi, Emiliano Salvatierra, Yanina Barbaglia, Félix Jimenez, Fabian E. Zalazar. Usefulness of rapid urease test samples for molecular analysis of clarithromycin resistance in Helicobacter pylori. Revista Argentina de Microbiología 2018; 50(4): 359 doi: 10.1016/j.ram.2017.11.005
|
| 16 |
M. A. Derbak, Ye. E. Dankanych, O. T. Ganich. POSSIBILITY OF HELICOBACTER PYLORI ERADICATION THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C . Bulletin of Problems Biology and Medicine 2020; 4(1): 113 doi: 10.29254/2077-4214-2020-4-158-113-117
|
| 17 |
Hidekazu Suzuki, Hideki Mori. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. Journal of Gastroenterology 2018; 53(3): 354 doi: 10.1007/s00535-017-1407-1
|
| 18 |
J. Molina‐Infante, D. Y. Graham, J. P. Gisbert. Editorial: quadruple therapy for H. pylori eradication is better than triple therapy – authors' reply. Alimentary Pharmacology & Therapeutics 2015; 41(7): 695 doi: 10.1111/apt.13113
|
| 19 |
Zhi-Qiang Song, Jian Liu, Li-Ya Zhou. Hybrid Therapy Regimen for Helicobacter Pylori Eradication. Chinese Medical Journal 2016; 129(8): 992 doi: 10.4103/0366-6999.179803
|
| 20 |
Bahare Salehi, Farukh Sharopov, Miquel Martorell, Jovana Rajkovic, Adedayo Oluwaseun Ademiluyi, Mehdi Sharifi-Rad, Patrick Valere Tsouh Fokou, Natália Martins, Marcello Iriti, Javad Sharifi-Rad. Phytochemicals in Helicobacter pylori Infections: What Are We Doing Now?. International Journal of Molecular Sciences 2018; 19(8): 2361 doi: 10.3390/ijms19082361
|
| 21 |
Xiaolin Zhang, Anmin Jiang, Guisheng Wang, Hao Yu, Banghua Qi, Youyi Xiong, Guoliang Zhou, Meisong Qin, Jinfeng Dou, Jianfei Wang. Fusion expression of the PGLa-AM1 with native structure and evaluation of its anti-Helicobacter pylori activity. Applied Microbiology and Biotechnology 2017; 101(14): 5667 doi: 10.1007/s00253-017-8302-9
|
| 22 |
Xiaolin Zhang, Anmin Jiang, Banghua Qi, Hao Yu, Youyi Xiong, Guoliang Zhou, Meisong Qin, Jinfeng Dou, Jianfei Wang. Secretion expression of human neutrophil peptide 1 (HNP1) in Pichia pastoris and its functional analysis against antibiotic-resistant Helicobacter pylori. Applied Microbiology and Biotechnology 2018; 102(11): 4817 doi: 10.1007/s00253-018-8982-9
|
| 23 |
Angel Cosme, Jacobo Lizasoan, Milagrosa Montes, Esther Tamayo, Horacio Alonso, Usua Mendarte, Maider Martos, María Fernández‐Reyes, Cristina Saraqueta, Luis Bujanda. Antimicrobial Susceptibility‐Guided Therapy Versus Empirical Concomitant Therapy for Eradication of Helicobacter pylori in a Region with High Rate of Clarithromycin Resistance. Helicobacter 2016; 21(1): 29 doi: 10.1111/hel.12231
|
| 24 |
György Miklós Buzás. Helicobacter pylori– 2014. Orvosi Hetilap 2015; 156(6): 203 doi: 10.1556/OH.2015.30097
|
| 25 |
Ana Campillo, Edurne Amorena, Miriam Ostiz, Marcos Kutz, Matilde LaIglesia. Triple terapia 10 días con esomeprazol 40 mg/12 h vs. cuádruple concomitante sin bismuto como tratamiento de primera línea de la infección por Helicobacter pylori. Gastroenterología y Hepatología 2016; 39(9): 584 doi: 10.1016/j.gastrohep.2016.03.002
|
| 26 |
Yong Hwan Kwon, Nayoung Kim, Ju Yup Lee, Yoon Jin Choi, Kichul Yoon, Ryung Hee Nam, Ji Hyung Suh, Jung Won Lee, Dong Ho Lee. Comparison of the efficacy of culture-based tailored therapy forHelicobacter pylorieradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study. Scandinavian Journal of Gastroenterology 2016; 51(3): 270 doi: 10.3109/00365521.2015.1095352
|
| 27 |
Javier Molina-Infante, David Y. Graham. Helicobacter pylori Research. 2016; : 471 doi: 10.1007/978-4-431-55936-8_20
|
| 28 |
Javier P. Gisbert, Javier Molina-Infante, Javier Amador, Fernando Bermejo, Luis Bujanda, Xavier Calvet, Manuel Castro-Fernández, Antonio Cuadrado-Lavín, J. Ignasi Elizalde, Emili Gene, Fernando Gomollón, Ángel Lanas, Carlos Martín de Argila, Fermín Mearin, Miguel Montoro, Ángeles Pérez-Aisa, Emilio Pérez-Trallero, Adrián G. McNicholl. IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori. Gastroenterología y Hepatología 2016; 39(10): 697 doi: 10.1016/j.gastrohep.2016.05.003
|
| 29 |
Diego Reyes, Javier Ortiz, Eduardo Fuentes-López, Sigall Budnik, Vicente Gándara, Andrea Gallardo, María Francisca Seydewitz, Roberto Candia, José Ignacio Vargas, María Paz Rollan, Javiera Godoy, Antonio Rollan, Rodrigo Mansilla, Alex Arenas, Javier Chahuán, Alberto Espino, Margarita Pizarro, Arnoldo Riquelme. Quadruple therapies are superior to standard triple therapy for Helicobacter pylori first-line eradication in Chile. Gastroenterología y Hepatología (English Edition) 2022; 45(7): 515 doi: 10.1016/j.gastre.2022.07.004
|
| 30 |
Bojan Tepes, Marko Kastelic, Miroslav Vujasinovic, Polona Lampic, Maja Seruga, Natasa Brglez Jurecic, Olga P. Nyssen, Maria G. Donday, Colm O’Morain, Francis Megraud, Adrian G McNicholl, Javier P. Gisbert. Helicobacter pylori treatment results in Slovenia in the period 2013-2015 as a part of European Registry on Helicobacter pylori Management. Radiology and Oncology 2017; 52(1): 1 doi: 10.1515/raon-2017-0055
|
| 31 |
Antonio Cuadrado-Lavín, J. Ramón Salcines-Caviedes, Ainhoa Diaz-Perez, Miguel F. Carrascosa, María Ochagavía, José Luis Fernandez-Forcelledo, Marta Cobo, Pedro Fernández-Gil, Blanca Ayestarán, Blanca Sánchez, Cristina Campo, Javier Llorca, Silvia Lorenzo, Aitziber Illaro. First-line eradication rates comparing two shortened non-bismuth quadruple regimens againstHelicobacter pylori: an open-label, randomized, multicentre clinical trial. Journal of Antimicrobial Chemotherapy 2015; 70(8): 2376 doi: 10.1093/jac/dkv089
|
| 32 |
Javier P. Gisbert, Javier Alcedo, Javier Amador, Luis Bujanda, Xavier Calvet, Manuel Castro-Fernández, Luis Fernández-Salazar, Emili Gené, Ángel Lanas, Alfredo Lucendo, Javier Molina-Infante, Olga P. Nyssen, A. Pérez-Aisa, Ignasi Puig. V Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterología y Hepatología (English Edition) 2022; 45(5): 392 doi: 10.1016/j.gastre.2021.07.001
|
| 33 |
Jing Yu, Peng Yang, Xiangrong Qin, Chunjian Li, Yiming Lv, Xiaoyong Wang. Impact of smoking on the eradication of Helicobacter pylori. Helicobacter 2022; 27(1) doi: 10.1111/hel.12860
|
| 34 |
Todor Asenov Angelov, Mila Dimitrova Kovacheva-Slavova, Hristo Ilianov Iliev, Hristo Yankov Valkov, Borislav Georgiev Vladimirov. Gastritis - New Approaches and Treatments. 2019; doi: 10.5772/intechopen.86963
|
| 35 |
Mercedes Ramas, Maria G. Donday, Adrian G. McNicholl, Javier P. Gisbert. Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial. Gastroenterología y Hepatología (English Edition) 2017; 40(10): 658 doi: 10.1016/j.gastre.2017.05.010
|
| 36 |
Yun Duk Jung, Yeon-Ji Kim, Woo Chul Chung. A Pilot Study ofHelicobacter pyloriEradication Using a Polymerase Chain Reaction-based Test for Clarithromycin Resistance. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2017; 17(4): 200 doi: 10.7704/kjhugr.2017.17.4.200
|
| 37 |
Zifang Shang, Siew Yin Chan, Qing Song, Peng Li, Wei Huang. The Strategies of Pathogen-Oriented Therapy on Circumventing Antimicrobial Resistance. Research 2020; 2020 doi: 10.34133/2020/2016201
|
| 38 |
Fazia Djennane-Hadibi, Mohamed Bachtarzi, Karim Layaida, Nassima Ali Arous, Mhamed Nakmouche, Berkane Saadi, Mohamed Tazir, Nadjia Ramdani-Bouguessa, Christophe Burucoa. High-Level Primary Clarithromycin Resistance ofHelicobacter pyloriin Algiers, Algeria: A Prospective Multicenter Molecular Study. Microbial Drug Resistance 2016; 22(3): 223 doi: 10.1089/mdr.2015.0209
|
| 39 |
Ran Han, Hong Lu, Ming-Wan Jiang, Ke-Wen Tan, Zhong Peng, Jia-Li Hu, Dian-Chun Fang, Chun-Hui Lan, Xiao-Ling Wu. Multicenter Study of Antibiotic Resistance Profile ofH. pyloriand Distribution of CYP2C19 Gene Polymorphism in Rural Population of Chongqing, China. Gastroenterology Research and Practice 2016; 2016: 1 doi: 10.1155/2016/8547686
|
| 40 |
Adrian G. McNicholl, Dmitry S. Bordin, Alfredo Lucendo, Galina Fadeenko, Manuel Castro Fernandez, Irina Voynovan, Natalia Valerievna Zakharova, Aiman Silkanovna Sarsenbaeva, Luis Bujanda, Ángeles Perez-Aisa, Liudmila Vologzhanina, Oleg Zaytsev, Tatiana Ilchishina, Cristobal de la Coba, Jorge Perez Lasala, Sergey Alekseenko, Ines Modolell, Javier Molina-Infante, Rafael Ruiz-Zorrilla Lopez, Horacio Alonso-Galan, Nuria Fernandez Moreno, Jen Hinojosa, Inmaculada Santaella, Pilar Varela, Pedro Luis Gonzalez-Cordero, Jesus Barrio, Jose Luis Dominguez-Jimenez, Oscar Nuñez, Javier Alcedo, Olga P. Nyssen, Maria Caldas, Maria G. Donday, Oleg Shvetz, Francis Megraud, Colm O'Morain, Javier P. Gisbert. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients. Clinical Gastroenterology and Hepatology 2020; 18(1): 89 doi: 10.1016/j.cgh.2019.03.048
|
| 41 |
Najat Bouihat, Christophe Burucoa, Ahmed Benkirane, Hassan Seddik, Sara Sentissi, Abderrahmane Al Bouzidi, Mustapha Elouennas, Amina Benouda. Helicobacter pylori Primary Antibiotic Resistance in 2015 in Morocco: A Phenotypic and Genotypic Prospective and Multicenter Study. Microbial Drug Resistance 2017; 23(6): 727 doi: 10.1089/mdr.2016.0264
|
| 42 |
Amir Hossein Miri, Mojtaba Kamankesh, Antoni Llopis-Lorente, Chenguang Liu, Matthias G. Wacker, Ismaeil Haririan, Hamid Asadzadeh Aghdaei, Michael R. Hamblin, Abbas Yadegar, Mazda Rad-Malekshahi, Mohammad Reza Zali. The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.917184
|
| 43 |
Angel Cosme, Milagrosa Montes, Begoña Ibarra, Esther Tamayo, Horacio Alonso, Usua Mendarte, Jacobo Lizasoan, Marta Herreros-Villanueva, Luis Bujanda. Antimicrobial susceptibility testing before first-line treatment for <i>Helicobacter pylori</i> infection in patients with dual or triple antibiotic resistance. World Journal of Gastroenterology 2017; 23(18): 3367-3373 doi: 10.3748/wjg.v23.i18.3367
|
| 44 |
Gamal M. El-Sherbiny, Mahmoud K. M. Elbestawy. A review – plant essential oils active againstHelicobacter pylori. Journal of Essential Oil Research 2022; 34(3): 203 doi: 10.1080/10412905.2022.2025464
|
| 45 |
Javier P. Gisbert, Adrian G. McNicholl. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter 2017; 22(4) doi: 10.1111/hel.12392
|
| 46 |
Javier P. Gisbert, Javier Alcedo, Javier Amador, Luis Bujanda, Xavier Calvet, Manuel Castro-Fernández, Luis Fernández-Salazar, Emili Gené, Ángel Lanas, Alfredo J. Lucendo, Javier Molina-Infante, Olga P. Nyssen, A. Pérez-Aisa, Ignasi Puig. V Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori. Gastroenterología y Hepatología 2022; 45(5): 392 doi: 10.1016/j.gastrohep.2021.07.011
|
| 47 |
Jing Yu, Chen Cui, Kai Ma, Peng Yang, Yizhou Jiang, Xiaoyong Wang. Effectiveness and safety of vonoprazan and amoxicillin dual regimen with Saccharomyces boulardii supplements on eradication of Helicobacter pylori. BMC Gastroenterology 2024; 24(1) doi: 10.1186/s12876-024-03524-0
|
| 48 |
Zhi-Qiang Song, Li-Ya Zhou. Hybrid, sequential and concomitant therapies for <i>Helicobacter pylori</i> eradication: A systematic review and meta-analysis. World Journal of Gastroenterology 2016; 22(19): 4766-4775 doi: 10.3748/wjg.v22.i19.4766
|
| 49 |
Nidhi Gupta, Shweta Maurya, Harshvardhan Verma, Vijay K. Verma. Unraveling the factors and mechanism involved in persistence: Host‐pathogen interactions in Helicobacter pylori. Journal of Cellular Biochemistry 2019; 120(11): 18572 doi: 10.1002/jcb.29201
|
| 50 |
Marjan Mokhtare, Mohammad Ebrahimian, Abolfazl Namazi, Amir M. Sadeghian, Hani Talaee, Mohsen Masoodi, Jiong Yu. The Efficacy of Paraprobiotic, Probiotic, and Mineral Supplementation on the Eradication Rate of Helicobacter pylori in Patients with Dyspepsia: A Randomized Clinical Trial. Advanced Gut & Microbiome Research 2024; 2024: 1 doi: 10.1155/2024/9936691
|
| 51 |
Skander Hathroubi, Stephanie L. Servetas, Ian Windham, D. Scott Merrell, Karen M. Ottemann. Helicobacter pylori Biofilm Formation and Its Potential Role in Pathogenesis. Microbiology and Molecular Biology Reviews 2018; 82(2) doi: 10.1128/MMBR.00001-18
|
| 52 |
Javier P. Gisbert, Javier Molina-Infante, Javier Amador, Fernando Bermejo, Luis Bujanda, Xavier Calvet, Manuel Castro-Fernández, Antonio Cuadrado-Lavín, J. Ignasi Elizalde, Emili Gene, Fernando Gomollón, Ángel Lanas, Carlos Martín de Argila, Fermín Mearin, Miguel Montoro, Ángeles Pérez-Aisa, Emilio Pérez-Trallero, Adrián G. McNicholl. IV Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterología y Hepatología (English Edition) 2016; 39(10): 697 doi: 10.1016/j.gastre.2016.11.007
|
| 53 |
Frank J Senatore, Jonathan Wilmot, John W Birk. Helicobacter pyloritreatment: Still a work in progress. Postgraduate Medicine 2016; 128(1): 152 doi: 10.1080/00325481.2016.1103194
|
| 54 |
Ana Campillo, Edurne Amorena, Miriam Ostiz, Marcos Kutz, Matilde LaIglesia. 10-day triple therapy with esomeprazole 40mg/12h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection. Gastroenterología y Hepatología (English Edition) 2016; 39(9): 584 doi: 10.1016/j.gastre.2016.10.007
|
| 55 |
Francisco Buitrago Ramírez, Cristina Gato Núñez, Manuel Tejero Mas, Nuria Rivera Jiménez, Francisco Luis Pérez Caballero. Criterios para la erradicación de Helicobacter pylori. FMC - Formación Médica Continuada en Atención Primaria 2018; 25(1): 43 doi: 10.1016/j.fmc.2017.03.009
|
| 56 |
Cláudia Sousa, Rute Ferreira, Nuno F. Azevedo, Mónica Oleastro, Joana Azeredo, Ceu Figueiredo, Luís D. R. Melo. Helicobacter pylori infection: from standard to alternative treatment strategies. Critical Reviews in Microbiology 2022; 48(3): 376 doi: 10.1080/1040841X.2021.1975643
|
| 57 |
Mercedes Ramas, Maria G. Donday, Adrian G. McNicholl, Javier P. Gisbert. Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial. Gastroenterología y Hepatología 2017; 40(10): 658 doi: 10.1016/j.gastrohep.2017.05.017
|
| 58 |
|
| 59 |
Javier Molina-Infante, Akiko Shiotani. Practical Aspects in Choosing a Helicobacter pylori Therapy. Gastroenterology Clinics of North America 2015; 44(3): 519 doi: 10.1016/j.gtc.2015.05.004
|